Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Millions of people with overactive bladder syndrome are prescribed daily anticholinergics. But research has linked these ...

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

The standard treatments for overactive bladder include lifestyle changes, bladder training, pelvic floor muscle training and anticholinergic (anti-muscarinic) drugs. Additional treatments for some ...

for the treatment of overactive bladder (OAB).This is the first time that CTAF has addressed this topic.

An overactive bladder may be temporary or become a chronic condition. How long the symptoms last may depend on factors like the underlying cause and treatment adherence. Some conditions may cause ...

When this happens, symptoms associated with overactive bladder are reduced. Medications that fall under the beta-3 adrenergic agonists class of drugs are Myrbetriq (mirabegron) and Gemtesa (vibegron).

Sunobinop tosylate is under clinical development by Imbrium Therapeutics and currently in Phase I for Overactive Bladder.